Moiz Areesha, Filion Kristian B, Tsoukas Michael A, Yu Oriana Hy, Peters Tricia M, Eisenberg Mark J
Centre of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; Division of Experimental Medicine, McGill University, Montreal, Canada.
Centre of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada; Department of Medicine, McGill University, Montreal, Canada.
Am J Med. 2025 Jun;138(6):934-940. doi: 10.1016/j.amjmed.2025.01.021. Epub 2025 Jan 31.
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have become central in managing obesity and type 2 diabetes, primarily through appetite suppression and metabolic regulation. This review explores the mechanisms underlying GLP-1 RA-induced weight loss, focusing on central and peripheral pathways. Centrally, GLP-1 RAs modulate brain regions controlling appetite, influencing neurotransmitter and peptide release to regulate hunger and energy expenditure. Peripherally, GLP-1 RAs improve glycemic control by enhancing insulin secretion, reducing glucagon release, delaying gastric emptying, and regulating gut hormones. They also reduce triglycerides and low-density lipoprotein cholesterol, mitigate adipose tissue inflammation, and minimize ectopic fat deposition, promoting overall metabolic health. Emerging dual and triple co-agonists, targeting GLP-1 alongside glucose-dependent insulinotropic polypeptide, and glucagon pathways, may enhance weight loss and metabolic flexibility. Understanding these mechanisms is crucial as the therapeutic landscape evolves, offering clinicians and researchers insights to optimize the efficacy of current and future obesity treatments.
胰高血糖素样肽-1(GLP-1)受体激动剂(RAs)已成为治疗肥胖症和2型糖尿病的核心药物,主要通过抑制食欲和调节代谢来发挥作用。本综述探讨了GLP-1受体激动剂诱导体重减轻的潜在机制,重点关注中枢和外周途径。在中枢,GLP-1受体激动剂调节控制食欲的脑区,影响神经递质和肽的释放,从而调节饥饿感和能量消耗。在外周,GLP-1受体激动剂通过增强胰岛素分泌、减少胰高血糖素释放、延缓胃排空和调节肠道激素来改善血糖控制。它们还能降低甘油三酯和低密度脂蛋白胆固醇,减轻脂肪组织炎症,并最大限度地减少异位脂肪沉积,促进整体代谢健康。针对GLP-1以及葡萄糖依赖性促胰岛素多肽和胰高血糖素途径的新型双靶点和三靶点共激动剂,可能会增强体重减轻效果和代谢灵活性。随着治疗领域的不断发展,了解这些机制至关重要,可为临床医生和研究人员提供见解,以优化当前和未来肥胖症治疗的疗效。